Tuberculosis diagnostics: which target product profiles should be prioritised?

SV Kik, CM Denkinger, M Casenghi… - European …, 2014 - Eur Respiratory Soc
SV Kik, CM Denkinger, M Casenghi, C Vadnais, M Pai
European Respiratory Journal, 2014Eur Respiratory Soc
4 Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease
caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of
antiviral resistance. Lancet 2013; 381: 2273–2279. 5 Wang W, Ren P, Mardi S, et al. Design
of multiplexed detection assays for identification of avian influenza a virus subtypes
pathogenic to humans by SmartCycler real-time reverse transcription-PCR. J Clin Microbiol
2009; 47: 86–92. 6 Centers for Disease Control and Prevention. Interim guidance on the use …
4 Hu Y, Lu S, Song Z, et al. Association between adverse clinical outcome in human disease caused by novel influenza A H7N9 virus and sustained viral shedding and emergence of antiviral resistance. Lancet 2013; 381: 2273–2279. 5 Wang W, Ren P, Mardi S, et al. Design of multiplexed detection assays for identification of avian influenza a virus subtypes pathogenic to humans by SmartCycler real-time reverse transcription-PCR. J Clin Microbiol 2009; 47: 86–92.
6 Centers for Disease Control and Prevention. Interim guidance on the use of antiviral agents for treatment of human infections with avian influenza A (H7N9) virus. www. cdc. gov/flu/avianflu/h7n9-antiviral-treatment. htm Date last accessed: January 9, 2014. Date last updated: September 30, 2013. 7 World Health Organization. Avian influenza A (H7N9) virus. www. who. int/influenza/human_animal_interface/influenza_h7n9/en/Date last accessed: January 9, 2014. Date last updated: May 31, 2013.
European Respiratory Society